Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
This list of potential positions covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty
Adaptimmune Therapeutics Plc (ADAP)
The company has return on total asset (ROA) of (0.2822) % which means that it has lost $0.2822 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8761) %, meaning that it created substantial loss on money invested by shareholders. Adaptimmune Therapeutics' management efficiency ratios could be used to measure how well Adaptimmune Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/19/2024, Return On Tangible Assets is likely to drop to -0.43. In addition to that, Return On Capital Employed is likely to drop to -0.69. As of 04/19/2024, Non Current Liabilities Total is likely to grow to about 178.8 M, while Total Current Liabilities is likely to drop slightly above 44.6 M. The entity currently falls under 'Small-Cap' category with a current market capitalization of 229.6 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Adaptimmune Therapeutics's market, we take the total number of its shares issued and multiply it by Adaptimmune Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Today, the firm appears to be undervalued. Adaptimmune Therapeutics shows a prevailing Real Value of $2.06 per share. The current price of the firm is $0.9. Our model approximates the value of Adaptimmune Therapeutics from analyzing the firm fundamentals such as return on equity of -1.88, and Profit Margin of (1.89) % as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor buying undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
argenx NV ADR (ARGX)
The company has return on total asset (ROA) of (0.0685) % which means that it has lost $0.0685 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0854) %, meaning that it created substantial loss on money invested by shareholders. Argenx NV's management efficiency ratios could be used to measure how well Argenx NV manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to drop to -0.11 in 2024. At this time, Argenx NV's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 439.7 M in 2024, whereas Other Current Assets are likely to drop slightly above 99.6 M in 2024. The firm currently falls under 'Large-Cap' category with a current market capitalization of 21.6 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Argenx NV's market, we take the total number of its shares issued and multiply it by Argenx NV's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Net Debt
(1.93 Billion)
Argenx NV reported Net Debt of (2.03 Billion) in 2023
BeyondSpring (BYSI)
The company has return on total asset (ROA) of (0.3869) % which means that it has lost $0.3869 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.1048) %, meaning that it created substantial loss on money invested by shareholders. BeyondSpring's management efficiency ratios could be used to measure how well BeyondSpring manages its routine affairs as well as how well it operates its assets and liabilities. The BeyondSpring's current Return On Equity is estimated to increase to 5.73, while Return On Tangible Assets are projected to decrease to (0.74). As of now, BeyondSpring's Debt To Assets are increasing as compared to previous years. The BeyondSpring's current Asset Turnover is estimated to increase to 0.03, while Total Assets are projected to decrease to under 43.6 M. The firm currently falls under 'Micro-Cap' category with a current market capitalization of 70.23 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BeyondSpring's market, we take the total number of its shares issued and multiply it by BeyondSpring's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Based on Macroaxis valuation methodology, the firm appears to be overvalued. BeyondSpring shows a prevailing Real Value of $1.43 per share. The current price of the firm is $1.8. Our model approximates the value of BeyondSpring from analyzing the firm fundamentals such as Shares Outstanding of 39.02 M, operating margin of (15.41) %, and Return On Equity of -3.1 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor purchasing undervalued instruments and trading away overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Cellectis SA (CLLS)
The company has return on total asset (ROA) of (0.1878) % which means that it has lost $0.1878 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7128) %, meaning that it created substantial loss on money invested by shareholders. Cellectis' management efficiency ratios could be used to measure how well Cellectis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.36 in 2024. Return On Capital Employed is likely to drop to -0.43 in 2024. At this time, Cellectis' Non Current Assets Total are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 212.3 M in 2024, whereas Non Currrent Assets Other are likely to drop 1,092 in 2024. The firm currently falls under 'Small-Cap' category with a current market capitalization of 181.16 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cellectis's market, we take the total number of its shares issued and multiply it by Cellectis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Net Debt
(14.03 Million)
At this time, Cellectis' Net Debt is comparatively stable compared to the past year.
ChemoCentryx (CCXI)
The company has return on total asset (ROA) of (18.55) % which means that it has lost $18.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (46.96) %, meaning that it created substantial loss on money invested by shareholders. ChemoCentryx's management efficiency ratios could be used to measure how well ChemoCentryx manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Mid-Cap' category with a current market capitalization of 3.64 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ChemoCentryx's market, we take the total number of its shares issued and multiply it by ChemoCentryx's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Corvus Pharmaceuticals (CRVS)
The company has return on total asset (ROA) of (0.2563) % which means that it has lost $0.2563 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5702) %, meaning that it created substantial loss on money invested by shareholders. Corvus Pharmaceuticals' management efficiency ratios could be used to measure how well Corvus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.62 in 2024. Return On Capital Employed is likely to drop to -0.64 in 2024. At this time, Corvus Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 72.5 M in 2024, whereas Other Current Assets are likely to drop slightly above 422.7 K in 2024. The entity currently falls under 'Micro-Cap' category with a current market capitalization of 69.14 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Corvus Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Corvus Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The firm has a beta of 0.3846. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Erytech Pharma will likely underperform. The beta indicator helps investors understand whether Erytech Pharma moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Erytech deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The entity currently falls under 'Micro-Cap' category with a current market capitalization of 29.57 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Erytech Pharma's market, we take the total number of its shares issued and multiply it by Erytech Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Please consider monitoring Macroaxis on a daily basis if you are holding a position in it. Macroaxis is trading at a penny-stock level, and the possibility of delisting is much higher compared to other privates. However, just because the private is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Macroaxis stock to be traded above the $1 level to remain listed. If Macroaxis private price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Macroaxis's Liquidity
Macroaxis financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Macroaxis's total debt and its cash.
Story appears to be empty
Adaptimmune Therapeutics Plc (ADAP)
The company has return on total asset (ROA) of (0.2822) % which means that it has lost $0.2822 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8761) %, meaning that it created substantial loss on money invested by shareholders. Adaptimmune Therapeutics' management efficiency ratios could be used to measure how well Adaptimmune Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/19/2024, Return On Tangible Assets is likely to drop to -0.43. In addition to that, Return On Capital Employed is likely to drop to -0.69. As of 04/19/2024, Non Current Liabilities Total is likely to grow to about 178.8 M, while Total Current Liabilities is likely to drop slightly above 44.6 M. The entity currently falls under 'Small-Cap' category with a current market capitalization of 229.6 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Adaptimmune Therapeutics's market, we take the total number of its shares issued and multiply it by Adaptimmune Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Today, the firm appears to be undervalued. Adaptimmune Therapeutics shows a prevailing Real Value of $2.06 per share. The current price of the firm is $0.9. Our model approximates the value of Adaptimmune Therapeutics from analyzing the firm fundamentals such as return on equity of -1.88, and Profit Margin of (1.89) % as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor buying undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
argenx NV ADR (ARGX)
The company has return on total asset (ROA) of (0.0685) % which means that it has lost $0.0685 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0854) %, meaning that it created substantial loss on money invested by shareholders. Argenx NV's management efficiency ratios could be used to measure how well Argenx NV manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to drop to -0.11 in 2024. At this time, Argenx NV's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 439.7 M in 2024, whereas Other Current Assets are likely to drop slightly above 99.6 M in 2024. The firm currently falls under 'Large-Cap' category with a current market capitalization of 21.6 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Argenx NV's market, we take the total number of its shares issued and multiply it by Argenx NV's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Net Debt
(1.93 Billion)
Argenx NV reported Net Debt of (2.03 Billion) in 2023
BeyondSpring (BYSI)
The company has return on total asset (ROA) of (0.3869) % which means that it has lost $0.3869 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.1048) %, meaning that it created substantial loss on money invested by shareholders. BeyondSpring's management efficiency ratios could be used to measure how well BeyondSpring manages its routine affairs as well as how well it operates its assets and liabilities. The BeyondSpring's current Return On Equity is estimated to increase to 5.73, while Return On Tangible Assets are projected to decrease to (0.74). As of now, BeyondSpring's Debt To Assets are increasing as compared to previous years. The BeyondSpring's current Asset Turnover is estimated to increase to 0.03, while Total Assets are projected to decrease to under 43.6 M. The firm currently falls under 'Micro-Cap' category with a current market capitalization of 70.23 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BeyondSpring's market, we take the total number of its shares issued and multiply it by BeyondSpring's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Based on Macroaxis valuation methodology, the firm appears to be overvalued. BeyondSpring shows a prevailing Real Value of $1.43 per share. The current price of the firm is $1.8. Our model approximates the value of BeyondSpring from analyzing the firm fundamentals such as Shares Outstanding of 39.02 M, operating margin of (15.41) %, and Return On Equity of -3.1 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor purchasing undervalued instruments and trading away overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Cellectis SA (CLLS)
The company has return on total asset (ROA) of (0.1878) % which means that it has lost $0.1878 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7128) %, meaning that it created substantial loss on money invested by shareholders. Cellectis' management efficiency ratios could be used to measure how well Cellectis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.36 in 2024. Return On Capital Employed is likely to drop to -0.43 in 2024. At this time, Cellectis' Non Current Assets Total are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 212.3 M in 2024, whereas Non Currrent Assets Other are likely to drop 1,092 in 2024. The firm currently falls under 'Small-Cap' category with a current market capitalization of 181.16 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cellectis's market, we take the total number of its shares issued and multiply it by Cellectis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Net Debt
(14.03 Million)
At this time, Cellectis' Net Debt is comparatively stable compared to the past year.
ChemoCentryx (CCXI)
The company has return on total asset (ROA) of (18.55) % which means that it has lost $18.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (46.96) %, meaning that it created substantial loss on money invested by shareholders. ChemoCentryx's management efficiency ratios could be used to measure how well ChemoCentryx manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Mid-Cap' category with a current market capitalization of 3.64 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ChemoCentryx's market, we take the total number of its shares issued and multiply it by ChemoCentryx's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Corvus Pharmaceuticals (CRVS)
The company has return on total asset (ROA) of (0.2563) % which means that it has lost $0.2563 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5702) %, meaning that it created substantial loss on money invested by shareholders. Corvus Pharmaceuticals' management efficiency ratios could be used to measure how well Corvus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.62 in 2024. Return On Capital Employed is likely to drop to -0.64 in 2024. At this time, Corvus Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 72.5 M in 2024, whereas Other Current Assets are likely to drop slightly above 422.7 K in 2024. The entity currently falls under 'Micro-Cap' category with a current market capitalization of 69.14 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Corvus Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Corvus Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The firm has a beta of 0.3846. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Erytech Pharma will likely underperform. The beta indicator helps investors understand whether Erytech Pharma moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Erytech deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The entity currently falls under 'Micro-Cap' category with a current market capitalization of 29.57 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Erytech Pharma's market, we take the total number of its shares issued and multiply it by Erytech Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Did you try this?
Run Portfolio Analyzer Now
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
